Skip to content

Nutritional Therapy in Patients With Post-extubation Dysphagia

Swallowing and Nutritional Therapy and Its Impact on Body Composition and Clinical Outcomes in Patients With Post-extubation Dysphagia

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06511284
Enrollment
128
Registered
2024-07-19
Start date
2024-07-01
Completion date
2027-12-01
Last updated
2024-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia

Keywords

enteral nutrition, nutritional assessment, nutritional therapy, Deglutition Disorders, rehabilitation

Brief summary

The aim of this study is to evaluate the impact of the prescription of two doses of protein on the amount in kilograms of muscle mass and on the clinical evolution (time until safe swallowing, time until removal of the feeding stoma, number of hospital readmissions, feeding stoma infections, incidence of pneumonia, functionality, number of falls, fractures and mortality) at 6 months after hospital discharge in patients with enteral nutrition due to post-extubation dysphagia.

Interventions

OTHERHigh protein dose

High dose of protein (2.0 g/kg) will prescribed for home enteral nutrition

OTHERUsual protein dose

Usual dose of protein (1.5 g/kg) will prescribed for home enteral nutrition

Sponsors

National Institute of Respiratory Diseases, Mexico
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Amounts of protein was not revealed for participants

Intervention model description

Randomized Clinical Trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who required invasive mechanical ventilation during their hospital stay with a diagnosis of post-extubation dysphagia diagnosed by fibroendoscopy evaluation of swallowing (FEES). * Patients who discharged with a feeding tube. * Patients with signed informed consent.

Exclusion criteria

* Patients with pre-existing dysphagia, or with neurological conditions that can cause dysphagia (e.g. multiple sclerosis, Parkinson's disease, Alzheimer's, myasthenia gravis). * Patients with chronic kidney disease, defined as a glomerular filtration rate \<60 ml/min. * Patients discharged with a terminal condition and/or life expectancy of less than 3 months. * Diagnosis of HIV, upon receiving clinical follow-up by the team of specialists.

Design outcomes

Primary

MeasureTime frameDescription
Muscle mass changesFrom randomization to 6 monthsChanges of muscle mass in kilograms measured by impedance bioelectric

Secondary

MeasureTime frameDescription
Duration of enteral nutrition indicationFrom randomization to 6 monthsTime from discharge to feeding tube removal
Feeding tube complicationsFrom randomization to 6 monthsNumber of feeding tube infections, dysfunctions and oclusions during study period
Muscle functionality changesFrom randomization to 6 monthsChanges in functionality measured by medical research council scale in a scale of 0-60 points
Handgrip strenght changesFrom randomization to 6 monthsChanges in functionality assessed by handgrip strenght in kilogramos using a digital dynamometer
Swallow recoveryFrom randomization to 6 monthsTime to safe swallowing diagnosed by fibroendoscopy evaluation of swallowing (FEES) and measured in months
Hospital readmissions associated to dysphagia complicationsFrom randomization to 6 monthsNumber of hospital readmissions assocciated to feeding tube infections, dysfunctions and oclusions during study period
6-month mortalityFrom randomization to 6 monthsAll-cause mortality during study period
Aspiration pneumonia incidenceFrom randomization to 6 monthsNumber of hospital readmissions due to aspiration pneumonia
Frailty complicationsFrom randomization to 6 monthsNumber of falls and fractures during study period

Countries

Mexico

Contacts

Primary ContactIvan A Osuna-Padilla, PhD
ivan.osuna@iner.gob.mx+5216671035806
Backup ContactAlan Garcia-Grimaldo, MSc
agarciag1716@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026